{"disease":{"id":"acute-osteomyelitis","name":"Acute osteomyelitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cloxacillin","indication_name":"Continuation Therapy for Acute Osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methocillin S","generic_name":"CLOXACILLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"cloxacillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Acute osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Acute osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Acute osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Acute osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dicloxacillin","indication_name":"Continuation Therapy for Acute Osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pathocil","generic_name":"DICLOXACILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Penicillin-class Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"oxacillin","indication_name":"Continuation Therapy for Acute Osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Acute osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06526884","title":"Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1080,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT01922011","title":"Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT03827980","title":"Long- and Midterm Outcomes of Osteoarticular Infections in Paediatric Patients","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Prof. Dr. Ulrich Heininger","has_results":false},{"nct_id":"NCT03846804","title":"Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Indiana University","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}